anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In clinical trials with podofilox gel, the following local adverse reactions were reported during the treatment of anogenital warts. The severity of local adverse reactions were predominantly mild or moderate and did not increase during the treatment period. Severe reactions were most frequent within the first 2 weeks of treatment.

Other local adverse reactions reported included stinging (7%), and erythema (5%); less commonly reported local adverse events included desquamation, scabbing, discoloration, tenderness, dryness, crusting, fissures, soreness, ulceration, swelling/edema, tingling, rash, and blisters.

The most common systemic adverse event reported during the clinical studies was headache (7%).

To report SUSPECTED ADVERSE REACTIONS, contact Padagis at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
SAH (subarachnoid hemorrhage) is a devastating medical emergency. As many as 60% of patients who are afflicted die in the first 30 days as a result of the SAH, or remain severely disabled from the bleed. Existing treatment options include: medical management; endovascular therapy and surgical therapy. Endovascular techniques using detachable coils have now been refined to include stents which serve to prevent the coil mass from dislodging. Further improvement is believed to be possible with the NEC which creates a seal to exclude the aneurismal lumen from blood flow without the need for coils. This study involves the endovascular placement of the NEC across the aneurysm neck in order to treat a subset of aneurysms without coils.
Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
Systems and methods for identifying tooth keypoints are disclosed. A method includes receiving digital representations comprising patient teeth, and identifying a first tooth outline from a first digital representation and a second tooth outline from a second digital representation. The method includes retrieving a 3D mesh comprising model teeth. The method includes projecting a first mesh boundary onto a patient tooth and modifying the first mesh boundary to match the first tooth outline. The method includes identifying a first tooth point on the first tooth outline that corresponds with a first mesh point on the first mesh boundary. The method includes mapping the first tooth point to the 3D mesh. The method includes determining that the first and second tooth points correspond to a common 3D mesh point. The method includes designating the first tooth point as a keypoint. The method includes modifying a digital representation based on the keypoint.
BACKGROUND: The currently available clinical therapeutic drugs for ulcerative colitis (UC) are considered inadequate owing to certain limitations. There have been reports on the anti-inflammatory effects of 2'-hydroxycinnamaldehyde (HCA). However, whether HCA can improve UC is still unclear. Here, we aimed to investigate the pharmacological effects of HCA on UC and its underlying molecular mechanisms.
METHODS: The pharmacological effects of HCA were comprehensively investigated in 2 experimental setups: mice with dextran sulfate sodium (DSS)-induced colitis and lipopolysaccharide (LPS)-treated fetal human colon (FHC) cells. Furthermore, the interaction between HCA and signal transducer and activator of transcription 3 (STAT3) was investigated using molecular docking. The FHC cells with STAT3 knockdown or overexpression and mice with intestinal epithelium-specific STAT3 deletion (STAT3ΔIEC) were used to evaluate whether STAT3 mediated the pharmacological effects of HCA.
RESULTS: 2'-Hydroxycinnamaldehyde attenuated dysregulated expression of inflammatory cytokines in a dose-dependent manner while increasing the expression of tight junction proteins, reducing the apoptosis of intestinal epithelial cells, and effectively alleviating inflammation both in vivo and in vitro. 2'-Hydroxycinnamaldehyde bound directly to STAT3 and inhibited its activation. The modulation of STAT3 activation levels due to STAT3 knockdown or overexpression influenced the mitigating effects of HCA on colitis. Further analysis indicated that the remission effect of HCA was not observed in STAT3ΔIEC mice, indicating that STAT3 mediated the anti-inflammatory effects of HCA.
CONCLUSIONS: We present a novel finding that HCA reduces colitis severity by attenuating intestinal mucosal barrier damage via STAT3. This discovery holds promise as a potential new strategy to alleviate UC.
YCANTH is a vesicant. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. Local skin reactions included vesiculation, pruritus, pain, discoloration, and erythema [see Adverse Reactions (6.1)]. 

Avoid application near the eyes and mucosal tissues, and to adjacent healthy skin. If YCANTH contacts any unintended surface, including healthy skin, immediately remove by wiping with a cotton swab or gauze.

Avoid other topical products (e.g. creams, lotions, or sunscreen) on treated areas until 24 hours after YCANTH treatment or until washing. Application of other topical products could spread YCANTH and cause blistering or other adverse reactions to healthy skin. 

If severe blistering, severe pain or other severe adverse reactions occur, remove YCANTH prior to the recommended 24 hours after administration by washing with soap and water.
BACKGROUND AND OBJECTIVE: Psychometric tests can provide important information for diagnostics and progression in chronic pain patients. Between 2008 and 2018, the electronic system painDETECT® was used in the outpatient pain clinic of the Hannover Medical School (MHH). The aim of this retrospective study was to evaluate the pain symptomatology data recorded using painDETECT® and the treatment procedures used in the patient cohort examined over a period of 15 months.
MATERIAL AND METHODS: A statistical analysis of baseline and follow-up data was performed. The analysis comprised pain-related parameters recorded by use of the painDETECT® system as well as outpatient records.
RESULTS: Baseline data of 459 patients (66% women) could be evaluated. The most common clinical pictures were spinal pain, headache, facial pain, and somatoform disorders, mostly with many years of previous treatment. Approximately 40% showed evidence of neuropathic pain components or central sensitization. With a mean pain intensity of VAS 6 (0-10), a predominantly high degree of chronicity was present. Approximately one third showed a high degree of pain-related functional impairment. Slightly more than half showed evidence of clinically relevant depression. Approximately 80% showed clinically relevant sleep disturbances. Follow-up data were available for 145 patients (31.6%). The proportion of patients receiving a nonpharmacological form of treatment increased by 44.1% (physical therapy) and by 24.1% (psychotherapeutic procedures) during the observation period. The use of co-analgesics increased by approximately 30% over the course.
CONCLUSION: In the outpatient setting, an extension of treatment can be successful for high-grade chronic pain patients. Close structural networking with the clinics for rehabilitation medicine and for psychosomatics and psychotherapy at the MHH can be a favorable prerequisite for this.
The present invention relates to health care beer and a preparation method thereof, which is characterized in that notoginseng beer is prepared by adding 0.1 to 10% of notoginseng, or 0.03 to 30 g/L of notoginseng extract products, or 0.01 to 0.1 g/L of panax notoginseng saponins in the brewing process of beer. The health care beer utilizes the characteristics and the physiological activity of notoginseng. The health care beer keeps original nutrition of beer, and simultaneously, the health beer also has the efficiency for improving the blood supply capability of a heart, improving blood circulation, reducing blood fat, promoting sleep, etc. Beer prepared according to the preparation method has special brisk taste. The preparation method has easy operation and has a good market perspective. The present invention adds a fire-new beer kind in beer markets.
Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
A number of previous studies have reported both neural and social cognition effects of intranasally administered oxytocin, although it is unclear whether functional effects are mediated by the peptide directly entering the brain or indirectly via raising peripheral concentrations. The investigators hypothesize that one method of producing a similar pattern of increased peripheral oxytocin concentrations but without the possibility of direct entry into the brain would be to administer the peptide lingually. In the current double-blind, between-subject, placebo controlled study 80 healthy male subjects will be recruited and receive either oxytocin (24IU) or placebo control administered orally (lingual). 45 minutes after treatment subjects will be required to complete both face emotion and emotional scene processing tasks during fMRI scanning. After the tasks, subjects will be required to rate their valence, intensity and arousal response to the same emotional face and scene stimuli which were presented during MRI acquisition. Blood samples will be taken before and 30 min after the oral treatment interventions to assess oxytocin blood concentrations. All subjects will be asked to complete a range of questionnaires before treatment to control for possible pre-treatment confounders in terms of personality traits and mood: Beck Depression Inventory II (BDI), Autism Spectrum Quotient (ASQ), Liebowitz Social Anxiety Scale (LSAS), State-Trait Anxiety Inventory (STAI), Childhood Trauma Questionnaire (CTQ), the Second Version of Social Responsiveness Scale(SRS-2), and Interpersonal Reactivity Index (IRI).
FIELD: medicine, particular, production of biologically active preparations from carrier in form of finely dispersed powder and liquid phase of various functional applications with uniform distribution of the latter on carrier surface. SUBSTANCE: the offered method of production of finely dispersed powder biological preparations consists in mixing of powder and liquid phase in rotating mixing vessel with inclined rotation axis and radial bottom with the help of inert radial bodies. Volume of liquid phase is taken equal to 0.5 and 40% of the total volume of powder particles. Total volume of inert bodies does not exceed the total volume of mixed components, and inert bodies are arranged in one layer. Such use of heavy inert bodies, radial in shape, rolling over radial bottom of mixing vessel without collision makes it possible to involve in the process thermolabile substances and to minimize the amount of liquid. On the basis of this invention, method of production of insectoacaricide dusts is devised by mixing powder carrier, mainly, of biological origin and solution of acting substance, mainly, of pyrethroides class, in volatile solvent with its subsequent removal by evaporation in stationary state. As a result, acting substance is uniformly distributed over all carrier particles that considerably affects efficiency of dusts. This method may be used in production of powdery concentrates of acting substances which are used in preparation of dusts and pelletized preparations. EFFECT: reduced material and power expenditures and extended potentials of used materials. 6 cl
Signs and symptoms vary in severity depending upon factors such as the amount of drug absorbed, the age of the patient, and the time elapsed since drug ingestion. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic toxicity. Other CNS manifestations may include drowsiness, stupor, ataxia, restlessness, agitation, delirium, severe perspiration, hyperactive reflexes, muscle rigidity, and athetoid and choreiform movements. Cardiac abnormalities may include tachycardia, signs of congestive heart failure, and in very rare cases, cardiac arrest. Respiratory depression, cyanosis, shock, vomiting, hyperpyrexia, mydriasis and oliguria or anuria, may also be present.
Cytokines, tumor cells, and tumor-associated macrophages play crucial roles in the composition of glioma tissue. Studies have demonstrated that certain cytokines can induce M2 polarization of tumor-associated macrophages and contribute to the progression of glioma. Nonetheless, the intricate molecular interactions among cytokines, glioma cells, and tumor-associated macrophages remain largely unexplored. To investigate this cross-talk, a combination of RNA-sequencing, chromatin immunoprecipitation, immunoprecipitation, exosome isolation, and biological experiments were employed. Treatment with IL-6 significantly increased circ-001422 expression in glioma cells. A poorer prognosis was associated with elevated levels of circ-001422 in glioma tissues. Circ-001422 was transcribed directly by STAT3 through binding to its promoter. Circ-001422 exerted cancer-promoting functions when co-cultured with M2 macrophages. Furthermore, glioma cells were found to transfer circ-001422 to macrophages via an exosomal pathway, promoting M2 polarization. Mechanically, circ-001422 interacted with p300, resulting in STAT3 acetylation, thus promoting nuclear localization and transcriptional activity of STAT3/NF-κB and M2 macrophage polarization. In conclusion, glioma cells released exosomes enriched with circ-001422, which in turn induce M2 macrophage polarization by activating the STAT3/NF-κB pathway, thereby enhancing the aggressive characteristics of glioma cells. Targeting circ-001422 may represent a potential therapeutic approach for glioma.
This invention describes a novel family of polysaccharide prodrugs with enhanced colonic delivery advantage. The prodrugs are synthesized by chemically linking a parent compound with a specially selected polysaccharide (M.W. 105-107 Da) containing galactose residues. Its characteristics are that it is synthesized by chemically linking polysaccharides with the parent compound through different bridge links for targeted colonic delivery; that the polysaccharides contain galactose residues. Because of this, the polysaccharide component can protect the parent compound from absorption (or metabolism) in the upper gastrointestinal tract and deliver a high concentration of the bound compound to the colonic area. Upon reaching the colon, the active component of the parent drug will be released locally from the polysaccharide via enzymatic hydrolysis, allowing it to act locally for colonic disease such as inflammation or infection and/or taking advantage of the favorable microenvironment in the colon for steady and stable colonic drug absorption.
This pilot study quantifies functional gains induced by the Electrically Assisted Movement Therapy (EAMT), an extension of Constraint-Induced Movement Therapy to moderately-to-severely paralyzed patients in their stable plateau phase of recovery. During EAMT, patients can assist affected upper limb movements through functional electrical stimulation. Initially, patients are divided in two groups. One of the groups receives EAMT, the other receives the best possible physical and occupational therapy. Therapy consists in 40 sessions of 45 minutes twice per day over five weeks, including a one-week therapy break. After 20 sessions, group allocation is crossed-over, and patients don't receive any therapy for one week.
Abstract of the disclosure Limulus test-positive plant glycolipid having the following properties:      Molecular weight:8,000?1,000 (SDS electrophoresis) Number of phosphorus: not less than l/mol. Number of hexosamine: 6?2/mol. Number of fatty acid: 6?2/mol. a method of stimulating the immune system of an animal. comprising to said animal an amount of said glycolipid effective to stimulate at least one of osteogenesis, oviposition and shell strength improvement of said animal. and an immuno stimulator composition comprising an effective amount of said glycolipid in admixture with a pharmaceutically of veterinarily acceptable carrier, such that when administered to an animal, the immune system of said animal is stimulated to effect at least one of osteogenesis, oviposition and shell strength improvement are disclosed.
The invention discloses an application of a moving point motor protein small molecular inhibitor to inhibition of tumor cell proliferation. The moving point motor protein small molecular inhibitor is a compound shown as a formula I or a formula II, and is named Syntelin. As proved by animal experiments, the Syntelin shown as a formula VII can be used for remarkably inhibiting the growth of human breast cancer cells. As proved by further mechanism experiments, the Syntelin shown as the VII formula can be used for inhibiting the walk of a CENP-E (Centromere Protein-E) motor on a micro-tube without influencing the interaction between the CENP-E and the micro-tube after being combined with the CENP-E. When the compound is added into a cell culture medium, the compound can enter cells to inhibit the function of the CENP-E, so that a part of chromosomes are arranged wrongly, and the activity of a spindle detection point is maintained for a long time. The CENP-E small molecular inhibitor Syntelin disclosed by the invention plays an important role in cell biology researches, and a basis can be laid for the research of novel chemotherapy medicaments by using the function of the inhibitor for controlling tumor cell proliferation. The formula I, formula II and formula VII are shown in the specifications.
BACKGROUND: The underlying mechanism of human umbilical-derived mesenchymal stem cells (hUC-MSCs) therapy for renal senescence in post-acute kidney injury (post-AKI) remains unclear. Unopposed mitochondrial fusion-based mitochondrial elongation is required for cellular senescence. This study attempted to dissect the role of hUC-MSCs therapy in modulating mitochondrial elongation-related senescence by hUC-MSCs therapy in post-AKI.
METHODS: Initially, a unilateral renal ischemia-reperfusion (uIRI) model was established in C57 mice. Subsequently, lentivirus-transfected hUC-MSCs were given by subcapsular injection. Two weeks after transplantation, histochemical staining, and transmission electron microscopy were used to assess the efficacy of hUC-MSCs in treating renal senescence, fibrosis, and mitochondrial function. To further investigate the mitochondrial regulation of hUC-MSCs secretion, hypoxic HK-2 cells were built. Finally, antibodies of HGF and its receptor were used within the hUC-MSCs supernatant.
RESULTS: Unopposed mitochondrial fusion, renal senescence, and renal interstitial fibrosis were successively identified after uIRI in mice. Then, the efficacy of hUC-MSCs after uIRI was confirmed. Subsequently, inhibiting hUC-MSCs-derived HGF significantly compromises the efficacy of hUC-MSCs and leads to ineffectively curbing mitochondrial elongation, accompanying insufficient control of elevated PKA and inhibitory phosphorylation of drp1 (Drp1pSer637). As a result, the treatment efficacy of renal senescence and fibrosis alleviation was also weakened. Furthermore, similar results were obtained with antibodies blocking HGF or cMet in hypoxic HK-2 cells treated with hUC-MSCs-condition medium for further proving. Uncurbed mitochondrial elongation induced by PKA and Drp1pSer637 was inhibited by hUC-MSCs derived HGF but reversed in the activation or overexpression of PKA.
CONCLUSIONS: The research concluded that hUC-MSCs-derived HGF can inhibit PKA-Drp1pSer637-mitochondrial elongation via its receptor cMet to alleviate renal senescence and fibrosis in post-AKI.
A medical instrument and a manufacturing method thereof are provided. The medical instrument includes a biomedical metal layer and a polymer film. The polymer film is a biodegradable polymer material. The manufacturing method includes the following steps: providing the biomedical metal layer, immersing the biomedical metal layer in a polymer solution, performing a baking process on the biomedical metal layer coated with a polymer film, forming the biomedical metal layer coated with the polymer film, taking out the biomedical metal layer coated with the polymer film to fabricate the medical instrument. The biodegradable polymer film and the biomedical metal layer are combined into the medical instrument, so that a physician performs a surgery more easily. In addition, decomposition time of the polymer film can be preset, so as to achieve efficacy of blocking soft tissue cells having a higher growth rate.
The present invention relates to capsules with grape seed extracts as raw materials. The capsules are composed of capsule shells and built-in powder, wherein the built-in powder comprises the following components by weight: 25 to 90% of procyanidin extracted from grape seeds, 10 to 30% of vitamin C and 0 to 62% of dietary fiber; the dietary fiber can be plant fiber or animal fiber. The present invention increases the proportion of procyanidin in the formulation, and overcomes the prejudice universally held by people that procyanidin can not be taken by a large dose. The present invention solves the technical problems of lower therapeutic effects, high product cost and side effect of capsules containing grape seed extracts. The present invention adopts the simple formulation of procyanidin and VC, and the procyanidin and the VC have mutually beneficial effects. The present invention has the effects on preventing biochemical components inside and outside cells from the attack of free radical, prolonging the service life of cells, resisting aging, softening blood vessels, improving microcirculation, inhibiting tumors, improving appetite, beautifying faces and removing speckles.
A device where saliva from a pregnant woman in the first trimester of pregnancy (6-8 weeks of pregnancy) is mixed with a chaotropic agent that facilitates cell lysis and protein denaturization. The mixture is introduced into a microfluidic system where the mixture is passed across a solid-state structure that captures all DNA in the mixture including cfDNA. After removal of protein and other waste from the membrane, the captured DNA is eluted from the solid-state structure into nucleic acid amplification reaction chambers. The system contains individual chambers for a positive control chamber and the target, male-specific, Y chromosome nucleotide sequence. The presence of amplification products is then detected in such a manner that a lay user can accurately determine the presence or absence of the Y chromosome. The presence of a Y chromosome is indicative of a biologically male fetus.